Sierra Oncology announced today that it has launched the MOMENTUM clinical trial for patients with myelofibrosis. The randomized double-blind global Phase 3 trial is designed to confirm the efficacy of momelotinib on myelofibrosis symptoms, transfusion independence, and splenomegaly, as compared to danazol. The trial is targeting enrollment of 180 myelofibrosis patients who are symptomatic, anemic and… Read More »SIERRA ONCOLOGY LAUNCHES THE MOMENTUM PHASE 3 CLINICAL TRIAL FOR PATIENTS WITH MYELOFIBROSIS
Official Title: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib CTI Biopharma is recruiting patients for the PACIFCA trial, a randomized phase 3 study evaluating Pacritinib in patients with myelofibrosis and less than 50,0000 platelet count who have never… Read More »NEW TRIAL RECRUITING PRIMARY, POST-PV, AND POST-ET MYELOFIBROSIS PATIENTS
ASH Clinical News reported on the results of an open-label, phase II clinical trial published in Blood. MPN patients were treated with pegylated-interferon and showed an overall response rate of approximately two-thirds in patients with high-risk essential thrombocythemia (ET) and polycythemia vera (PV). A total of 115 patients were enrolled: 65 patients with ET and 50 patients… Read More »PEGYLATED INTERFERON LEADS TO HIGH RESPONSE RATES IN ET & PV AFTER HYDROXYUREA
Your copy of the Fall 2019 Newsletter from the MPN Research Foundation is now available. Filled with the latest news from the global MPN community, the Fall 2019 newsletter includes information about MPNRF’s 2019 – 2020 MPN Challenge™ Grant awardees, an inspiring story about MPN women warriors who are making a difference one step at… Read More »THE FALL 2019 NEWSLETTER IS HERE
Participate in a New Online Survey by Patient Power As researchers around the world seek to accelerate progress in medicine it’s important for patients to share their stories to promote greater understanding. To that end, Patient Power has partnered with Dr. Naveen Pemmaraju, an MPN researcher and clinician at The University of Texas MD Anderson Cancer Center in Houston to… Read More »PATIENT POWER’S MPN PATIENT SURVEY
The Big Day is Here, Rare Cancer Day. The National Organization for Rare Disorders (NORD) developed a day devoted to raising awareness about rare cancers. Spearheaded by the NORD Rare Cancer Coalition, which is comprised of 24 rare cancer-specific Member Organizations, Rare Cancer Day will be observed today, Oct 1 to highlight the challenges people… Read More »TODAY IS RARE CANCER DAY!
More possible good news for upcoming therapies for myeloproliferative neoplasms. Geron was granted fast-track designation by FDA for imetelstat, which they have pursued in people with Intermediate-2 Myelofibrosis OR who have relapsed after or who are refractory to a JAK inhibitor such as Jakafi or Inrebic. About Imetelstat Imetelstat is a novel, first-in-class telomerase inhibitor… Read More »GERON RECEIVES FAST TRACK DESIGNATION TO IMETELSTAT FOR MYELOFIBROSIS
“Myelofibrosis in myeloproliferative neoplasms (MPNs) with mutations such as JAK2V617F is an unfavorable sign for uncontrollable disease progression in the clinic and is complicated with osteosclerosis whose pathogenesis is largely unknown. Because several studies have revealed that macrophages are indispensable supporter for bone forming osteoblasts, we speculated that macrophages might play a significant role in the proliferation of collagen-producing… Read More »VITAMIN D RECEPTOR-MEDIATED SKEWED DIFFERENTIATION OF MACROPHAGES INITIATES MYELOFIBROSIS AND SUBSEQUENT OSTEOSCLEROSIS.
“Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first 2 years and hence we aimed to analyze the outcome of 2-year disease-free survivors. 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow… Read More »LONG-TERM OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELOFIBROSIS.
Imago BioSciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of IMG-7289 (bomedemstat) for the treatment of myelofibrosis. “Myelofibrosis remains a major unmet clinical need imposing on patients a great burden of disease. IMG-7289 shows promise to meet this need of relieving patient’s symptoms and improving their… Read More »IMAGO BIOSCIENCES GRANTED FAST TRACK DESIGNATION FOR IMG-7289 IN MYELOFIBROSIS
